Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Published

Emerging from the dark side: new therapeutic applications of scheduled psychoactive substances.

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal
Future medicinal chemistry
Date
2019-02-01
Source
PubMed
DOI
10.4155/fmc-2018-0447
PubMed
30763121

Authors

James ERobertshaw TLWestwell AD
Watch author

Derived topics and classifications

psilocybin General Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-09-11PsilocybinReactions Weekly · 2026-10-03Placebo, Psilocybin und der vermaledeite p-WertNervenheilkunde · 2026-10-01Embeddedness under psilocybin.Nature neuroscience · 2026-10-01The New Mexico Medical Psilocybin Act and current trends in the United States psychedelic policyPsychedelics · 2026-10-01Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMTJAMA Network Open · 2026-09-29Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-09-24